Business Context and Reporting Period
Company: DaVita Inc. (DVA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: DaVita is a leading provider of kidney care services, primarily operating a U.S. dialysis business serving approximately 200,500 patients across 2,657 centers. The company also operates ancillary services including U.S. Integrated Kidney Care (IKC), international dialysis operations (585 centers in 14 countries), and other ancillary services. The company reported a net increase in consolidated patient growth of 4.9% for the year.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $13,643 million | $12,816 million | +6.5% |
| Operating Income | $2,044 million | $2,090 million | -2.2% |
| Adjusted Operating Income | $2,094 million | $1,981 million | +5.7% |
| Net Income (Attributable to DaVita Inc.) | $747 million | $936 million | -20.2% |
| Operating Cash Flow | $1,887 million | $2,022 million | -6.7% |
| Free Cash Flow | $1,024 million | $1,162 million | -11.9% |
| Long-Term Debt (Principal) | $10,345 million | $9,511 million | +8.8% |
| Cash and Equivalents | $676 million | $795 million | -15.0% |
Note: Adjusted Operating Income excludes non-recurring items such as cybersecurity charges and gains on changes in ownership interests.
Material Changes vs. Prior Period
- Revenue Growth: Total consolidated revenue increased 6.5% to $13.6 billion. U.S. dialysis revenue grew 3.5% driven by a $18.24 increase in average patient service revenue per treatment. Ancillary services revenue surged 27.3%, primarily due to international operations growth.
- Profitability Pressure: GAAP Operating Income declined 2.2% to $2.0 billion, impacted by a $25 million charge related to a cybersecurity incident and the absence of a $109 million non-cash gain on changes in ownership interests recognized in 2024. Adjusted Operating Income increased 5.7%.
- Treatment Volume: U.S. dialysis treatments decreased 1.1% to 28.7 million, attributed to elevated mortality rates and a severe flu season.
- Cost Increases: Patient care costs per treatment rose 5.9% to $273.34, driven by pharmaceutical costs (specifically phosphate binders) and increased labor rates.
- Capital Structure: The company refinanced its Term Loan A-1 and B-1 facilities with new Term Loan A-2 and B-2 facilities and issued $1.0 billion of 6.75% senior notes due 2033. Debt expense increased 23.4% to $580 million.
Guidance, Outlook, and Risks
Management Outlook for 2026
- Treatment Volumes: Expected to be approximately flat in the U.S. dialysis business, assuming slight improvement in flu impact but continued elevated mortality.
- Operating Income: Management expects growth driven by revenue per treatment improvements (rate increases and collections) partially offset by inflationary cost increases (labor and supplies).
- Phosphate Binders: The impact on operating income is expected to be approximately flat year-over-year.
- Debt Expense: Expected to decrease in 2026 due to recent financing transactions.
Key Risks and Contingencies
- Cybersecurity: A significant incident in April 2025 resulted in data exfiltration and operational disruption, incurring approximately $25.2 million in remediation charges. The company continues to incur expenses related to remediation and litigation.
- Regulatory Environment: Significant exposure to changes in Medicare ESRD Prospective Payment System (PPS) rates and policies. The inclusion of phosphate binders in the bundled payment rate (with transitional add-on payments) introduces uncertainty regarding future reimbursement adequacy.
- Commercial Payor Mix: Profitability is highly sensitive to the percentage of patients with commercial insurance. Risks include the expiration of enhanced premium tax credits and restrictive plan designs by payors.
- Legal Proceedings: The company is subject to various investigations (e.g., U.S. Attorney New Jersey, California Department of Insurance, FTC) and lawsuits regarding billing practices, antitrust matters, and charitable premium assistance. Accruals for these matters were deemed immaterial as of year-end.
Investor Verification Checklist
- Cybersecurity Impact: Verify the ongoing financial impact of the April 2025 cyber incident on billing cycles, collections, and future remediation costs beyond the initial $25.2 million charge.
- Phosphate Binder Reimbursement: Monitor CMS guidance on the Transitional Drug Add-on Payment Adjustment (TDAPA) for phosphate binders and the potential margin impact when these drugs are fully incorporated into the ESRD PPS bundle post-2026.
- Commercial Patient Mix: Track the percentage of patients covered by commercial insurance versus government programs, as commercial payors generate nearly all non-acute dialysis profits.
- Debt Covenants: Confirm continued compliance with leverage ratio covenants (target range 3.0x to 3.5x Consolidated EBITDA) given the increased debt load and interest expense.
- Legal Accruals: Review Note 15 for updates on the status of the U.S. Attorney New Jersey investigation and the California Department of Insurance inquiry, as adverse outcomes could result in significant penalties.